Core Viewpoint - Hims & Hers Health's stock has experienced a significant decline following the termination of its sales partnership with Novo Nordisk, amid allegations of improper practices related to the sale of compounded semaglutide, a key weight loss drug [2][7][13]. Group 1: Company Overview - Hims & Hers Health has leveraged the popularity of weight loss drugs, particularly GLP-1 agonists like Wegovy, to become a top market performer, with its stock rising nearly 100% over the past year before the recent downturn [2][4]. - The company grew its subscriber base from 391,000 in Q1 2021 to 1.7 million in Q1 2024, indicating strong growth in its overall business model, which includes various health and wellness products [9]. Group 2: Recent Developments - Novo Nordisk terminated its sales partnership with Hims & Hers due to the latter's continued sale of compounded semaglutide, which Novo Nordisk claims is an abuse of compounding practices to bypass patent protections [2][7]. - Hims & Hers began selling compounded semaglutide in May 2024, which contributed to its recent success, but the company was expected to cease this practice after the end of the semaglutide shortage in February [6][10]. Group 3: Allegations and Impact - Novo Nordisk has made serious allegations against Hims & Hers, including deceptive marketing practices and illegal mass compounding, which could potentially harm the company's brand and reputation [11][14]. - The company's management has provided sales guidance for 2025 of $2.3 billion to $2.4 billion, with approximately 30% of revenue expected from weight loss drugs, highlighting the importance of this segment to its overall business [10].

Hims & Hers' (HIMS 11.76%) stock crashed over 30% following news highlighting the end of its relationship with Novo Nordisk (NVO 0.63%).*Stock prices used were the afternoon prices of June 22, 2025. The video was published on June 24, 2025. ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and illegal practices that have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4]. Group 2: Partnership Termination and Stock Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant financial harm to investors [5]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct to support the investigation [7].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of Novo Nordisk's weight loss drug, Wegovy® [3][4][5] Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3] Group 2: Legal Allegations - The class action lawsuit claims that during the class period from April 29, 2025, to June 23, 2025, the company made false or misleading statements and failed to disclose material facts [4] - Allegations include that Hims & Hers was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4] - The lawsuit also suggests that there was a significant risk of Novo Nordisk terminating its collaboration with Hims & Hers due to these practices [4] Group 3: Impact of the Lawsuit - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing concerns over deceptive practices that endangered patient safety [5] - Following this announcement, shares of Hims & Hers experienced a decline of over 34% [5]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements and the promotion of illegitimate products, which led to a significant drop in stock price following the termination of a partnership with Novo Nordisk [1][2]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - Following the allegations, Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason [2]. - The lawsuit claims that the stock price of Hims & Hers fell by more than 34% after the announcement of the partnership termination [2]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [3]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [3]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [4]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [4].

Core Viewpoint - A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose risks related to its promotion of illegitimate versions of Wegovy, leading to a significant stock price drop after the termination of its partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Hims & Hers securities between April 29, 2025, and June 23, 2025 [1]. - The complaint alleges that Hims & Hers engaged in deceptive practices that jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [2]. Group 2: Stock Impact - Following the announcement of the termination of the partnership with Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [2]. Group 3: Investor Information - Investors who acquired shares of Hims & Hers are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on August 25, 2025 [3].

Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits following the termination of its collaboration with Novo Nordisk due to concerns over deceptive marketing practices related to the weight loss drug Wegovy® [1][2][4]. Group 1: Lawsuits and Allegations - The lawsuits, filed in Northern California, seek to represent investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [1][3]. - Allegations include that Hims & Hers made false and misleading statements and failed to disclose critical information regarding the safety and legality of its marketing practices [4][5]. - The complaints specifically mention that the company engaged in deceptive promotion and selling of knockoff versions of Wegovy®, which posed risks to patient safety and jeopardized its collaboration with Novo Nordisk [4][5]. Group 2: Impact of Novo Nordisk's Decision - Novo Nordisk announced the termination of its collaboration with Hims & Hers on June 23, 2025, citing concerns over illegal mass compounding and deceptive marketing practices [2][5]. - The announcement led to a significant 30% drop in the share price of Hims & Hers [2]. - Novo Nordisk emphasized that Hims & Hers failed to comply with legal standards regarding the sale of compounded drugs, which raised serious patient safety concerns [5]. Group 3: Investigation and Investor Actions - Hagens Berman, a national shareholders rights firm, is investigating the legal claims and encourages affected investors to report their losses [3][6]. - The firm is also seeking information from individuals who may assist in the investigation, highlighting the potential for whistleblower rewards under the SEC Whistleblower program [6].

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific allegations include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 2: Participation Information - Investors who purchased Hims common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Here are some stocks on the move. There obviously are many today. Hims and Hers is pacing for its worst week ever.You flag this to our our crew. It's something that I've never seen before. So, the stock started this week with a 35% crash because they had a joint venture with um Novo Nordisk to sell legitimate ver I shouldn't say legitimate to sell branded version of Wevy versus the compounded version that they've been selling.and then Novo Nordisk after a month put out a press release basically accusing the ...